Frequencies for first 10,000 rows of rx8v2c2 variable in nhamcsopd2006 dataset :

        for rx8, level 2 of multum drug |
                            category #2 |      Freq.     Percent        Cum.
----------------------------------------+-----------------------------------
          Anti-infectives: sulfanomides |          3        0.03        0.03
Metabolic agents: antihyperlipidemia ag |          2        0.02        0.05
    Cardiovascular agents: vasodilators |          5        0.05        0.10
                   CNS: Anticonvulsants |          8        0.08        0.18
CNS: Antiemetic/antivertigo agents: 5HT |          9        0.09        0.27
            CNS: Anti-Parkinson agents  |          1        0.01        0.28
Coagulation modifiers: antiplatelet age |         17        0.17        0.45
    Hormones: adrenal cortical steroids |          1        0.01        0.46
Miscellaneous agents: local injectable  |          2        0.02        0.48
Miscellaneous agents: genitourinary tra |          2        0.02        0.50
Nutritional products: minerals and elec |          4        0.04        0.54
     Respiratory agents: antihistamines |          1        0.01        0.55
       Respiratory agents: antitussives |          3        0.03        0.58
Respiratory agents: miscellaneous respi |          1        0.01        0.59
  Topical agents: dermatological agents |          1        0.01        0.60
   Miscellaneous agents: antirheumatics |          1        0.01        0.61
Alternative medicines: nutraceutical pr |          1        0.01        0.62
Metabolic agents: antihyperuricemic age |          1        0.01        0.63
Miscellaneous agents: smoking cessation |          4        0.04        0.67
Cardiovascular agents: aldosterone rece |          8        0.08        0.75
                                      . |      9,925       99.25      100.00
----------------------------------------+-----------------------------------
                                  Total |     10,000      100.00

by Jean Roth , jroth@nber.org , 28 Mar 2016